Our Team

About Us

We are a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases. We see new ways to healthier vision.
Rahul Bhola, MD, MBA
David S. Boyer, MD
Clinical Advisor
Jeffrey Heier, MD
Clinical Advisor
Arshad M. Khanani, MD, MA
Clinical Advisor
Carl D. Regillo, MD, FACS
Clinical Advisor
Kuldev Singh, MD, MPH
Clinical Advisor
Rishi P. Singh, MD
Clinical Advisor
Brian Gilger, DVM, DACVO, DABT
Scientific Advisor
Matt Hirsch, PhD
Scientific Advisor
François Paquet-Durand, PhD
Scientific Advisor
Christy Shaffer, PhD
Chair, Board of Directors; Member, Nominating and Corporate Governance Committee; Member, Audit Committee
Christina Ackermann
Chair, Nominating and Corporate Governance Committee; Member, Compensation Committee
Julie Eastland, MBA
Chair, Audit Committee
Eric Bjerkholt, MBA
Chair, Compensation Committee; Member, Audit Committee
Fred Guerard, PharmD
Board Member
Dirk Sauer, PhD
Member, Nominating and Corporate Governance Committee Chair, Science and Innovation Committee
Fred Guerard, PharmD
Chief Executive Officer
Robert S. Breuil
Chief Financial Officer
Parisa Zamiri, MD, PhD
Chief Medical Officer
Bettina Maunz
Chief People Officer
Ming Yang, PhD
SVP, Research & Development
Ali Kakavand, PhD
VP, Head of Program Management
Niall Murphy
VP, Finance
Marither S. Chuidian, MD, MPH
VP, Medical Affairs
Fang Li, PhD, RAC
VP, Regulatory Affairs
Jen Watts
VP, Clinical Operations
Han Wettenstein
VP, Controller
Sara Mary Hall
Gene Therapy Program Lead
Every day, Graybug works relentlessly to make healthy vision more accessible and more manageable for patients with vision-threatening eye diseases.
Explore Our Pipeline